Close Menu

GenomeWeb

In early 2020, the direct-to-consumer genetic test developer laid off about 14 percent of its workforce amid a restructuring of its consumer business.

The system is based on GNA's proprietary pulsed control amplification technology, which uses short electrical pulses to drive rapid amplification cycles.

The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.

Cowen highlighted the company's potential for allowing proteomics experiments at scale, allowing for deep proteomic measurements at high throughput.

The New York Times reports the first case of the SARS-CoV-2 strain that is suspected to be more infectious has been identified in the US.

The Verge reports that the EU-UK trade deal includes a provision that the transfer of DNA profiles rely on outdated email software.

The UK's Medicines and Healthcare products Regulatory Authority has approved the SARS-CoV-2 vaccine from Oxford University and AstraZeneca, the Guardian reports.

In Cell this week: functional changes in bacteria and yeast due to protein structure alterations, C. elegans NeuroPAL labeling strategy, and more.

The tumor microenvironment (TME) is comprised of an array of cell types, including immune and inflammatory cells, adipose cells, neuroendocrine cells, and cancer-associated fibroblasts. Additionally, blood and lymphatic vascular networks and extracellular matrix components create a diverse and multifaceted situation. Understanding how all of these elements interact requires the ability to distinguish individual cell types--something that is difficult to do using bulk cell approaches. Single cell gene expression analyses offer a high-resolution understanding of the TME.

Carrier screening to detect the presence of heritable genetic defects has been an important element of reproductive health strategies for over 50 years. Until recently, however, the practice has been restricted to a limited number of single-gene tests offered mainly to higher-risk individuals or populations based on race, ethnicity, or ancestry. But the landscape of carrier screening and its role in reproductive health are changing fast.